ArticleBMC cancer2019

Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial.

Sarah R Brown et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.